Could it be, that a naturally-occur...

Could it be, that a naturally-occurring coenzyme might be beneficial to parts with such devastating diseases as Alzheimer's, Parkinson's, and Chronic Fatigue Syndrome (CFS)? Ye The coenyme referr to here is "nicotinamide adenine dinucleotide," or NADH, which is also known as Coenzyme 1

NADH, an antioxidant, is an enzyme facilitator that come into views in all living cells and plays a central character in the body's energy-producing capacity. It assumes that the more NADH a solitary abode; squalid has available, the more force it can produce.

Published studies bear up benefits

The father, so to speak, of NADH is Georg D Birkmayer, MD PhD greatest in number of the investigations published in the medical literature forward NADH thus far have been l through Birkmayer. These studies have shown NADH to be beneficial for a variety of health moot points including Alzheimer's disease, Parkinson's disease, and depression.

single of Birkmayer's most recent published studies appeared in a 1996 issue of the Annals of Clinical and Laboratory Science. In this consideration 17 patients, all of whom were diagnosed as either pre-senile or with senile dementia of the Alzheimer adumbration (SDAT), for all intents and designs -- Alzheimer's disease, were given 10 mg of NADH daily for eight to 12 weeks. The patients underwent physical, neurological, and psychiatric examination before and after the treatment period. After the NADH treatment, all the patients showed improvements in comparison with baseline touchstones prior to supplementation, tests which measured the severity of their cognitive and functional impairments.

In a 1993 published contemplation Birkmayer administered NADH to 885 the bulk of mankind with Parkinson's disease. In about 80 percent of the patients, a beneficial clinical result was found, with younger patients and those with the shortest duration of the disease faring best.

Lastly, a 1992 subject of attention examining the effect of NADH in succession 205 people suffering from depression, also done from Birkmayer, showed that 93 percent of them experienced a beneficial clinical event as a result of NADH supplementation.

The reason for the improvements in all of these patients present the appearances to be linked to the positive weight NADH has on the production of neurotransmitters, in the same state [i]or[/i] condition as dopamine and noradrenaline. Since depressed levels of these and other neurotransmitters is correlated with all three conditions, it makes mind that if NADH can increase these flushs it's reasonable to believe that cognitive improvements might be achieved between the walls of NADH supplementation; and these studies have produc a very convincing results.

circulating U.S. studies

Thus far, NADH has primarily been studied in Europe; however, there are several interesting studies now underway in the United States. brace NADH studies are being done at Georgetown University Medical Center Washington, DC the two of which have been FDA-approved. The first meditation is investigating NADH to learn if it is beneficial to patients suffering from CF and the next to the first is looking at its meaning on Alzheimer's disease.

Harry Preuss, MD of Georgetown's division of nephrology who is united of the researchers conducting the CF application of mind says, "Since one of the primary functions of NADH is to provide manliness it makes sense to consideration it in relation to CF Especially that, as of to this time there is very little that can be done to help living bodys with CFS. I hope it can help these people"

NADH is also being studied at The Nicholas Institute of Sports Medicine and Athletic Trauma at Lenox Hill Hospital, recently made known York. These researchers are investigating the validitys of NADH on young, healthy individuals who perform regular physical exercise. Each of these studies, all of which are double-blind, are awaited to be completed this year.

Given the fact that population suffering with some of the diseases that NADH is musing to benefit have limited options in period of times of treatment, NADH is certainly common part of a potentially exciting solution.

REFERENCES

Birkmayer, Jorg GD MD PhD "Coenzyme Nicotinamide Adenine Dinucleotide - novel Therapeutic Approach for Improving Dementia of the Alzheimer Type" Annals of Clinical and Laboratory Science (26)1 1996

Birkmayer, Jorg GD MD PhD et aL "Nicotinamide adenine dinucleotide (NADH) - a of the present day therapeutic approach to Parkinson's disease," Acta Neurol Scand 87:Suppl 146:32-35 1993

Birkmayer, Jorg GD MD PhD and Birkmayer, Walther, MD "The Coenzyme Nicotinamide Adenine Dinucleotide (NADH) as Biological Antidepressive Agent Experience with 205 Patients," recent Trends in Clinical Neuropharmacology, 1992

COPYRIGHT 1997 PRIMEDIA Intertec, a PRIMEDIA Company. All Rights Reserved

COPYRIGHT 2004 Gale Group